The rest of this page explains the two receptors it works through, what published reviews report about blood sugar and body weight, what a prescriber looks at before writing it, which lab markers show the metabolic picture over time, and which symptoms need urgent attention.
It is a single engineered peptide that switches on two gut hormone receptors at the same time, the GIP receptor and the GLP-1 receptor 1. A licensed prescriber decides whether tirzepatide is appropriate for a particular person, and that decision follows a review of medical history, current medicines, lab work and goals.
The two hormone systems it borrows from are both incretins, the signals your gut releases when food arrives. GIP is short for glucose-dependent insulinotropic polypeptide. GLP-1 is short for glucagon-like peptide-1. Both act on the pancreas, the brain and the digestive tract, and reviews describe this molecule as acting at both receptors rather than one 2.
That dual action is what makes it structurally different from the earlier medicines in the same family, which worked through the GLP-1 receptor alone. Reviews describe it as first in its class on that basis 1.
In practical terms, it is a prescription medicine, not a supplement, not a peptide bought online, and not something a person starts or stops on their own judgement. How it is prescribed and how it is followed is decided by your clinician after an evaluation, and nothing on this page replaces that conversation.
It copies the signals of two incretin hormones, which changes how the pancreas releases insulin after food, how quickly the stomach empties, and how strongly appetite signals register in the brain 2.
The insulin effect described in reviews is glucose-dependent, meaning the signal to release insulin is strongest when blood glucose is already rising 2. The same incretin signalling reduces glucagon output from the pancreas, and glucagon is the hormone that tells the liver to push stored glucose back into the bloodstream.
Slower stomach emptying matters for a different reason. When food leaves the stomach more gradually, the glucose rise after a meal is flatter and fullness lasts longer into the afternoon. That is why appetite and portion size shift for some people rather than willpower suddenly improving.
The GIP receptor adds a second lever on top of that. Research suggests that acting on both receptors influences insulin sensitivity and how fat tissue handles energy, not only how much insulin the pancreas releases 3. Insulin sensitivity is the quieter half of the story here. When muscle and liver respond poorly to insulin, the pancreas compensates by producing more of it, and that pattern sits underneath a lot of stubborn metabolic lab work.
None of this happens in isolation from food, sleep, training and stress. A medicine changes the slope of the hill, it does not remove the hill.
The difference is the second receptor. Single-receptor medicines in this family act on the GLP-1 receptor; this one acts on the GIP receptor as well, which is the defining feature reviews use to classify it 1.
If the GLP-1 side of the family is new to you, the background is covered in our explainer on what GLP-1 is and what it does.
The second receptor is not a cosmetic difference. Studies indicate that the dual approach produced stronger improvement in glycaemic control and larger body weight reduction than the comparator medicines examined in people with type 2 diabetes 4. That is a statement about group averages in published work, not a forecast for any individual, and a licensed provider is the person who weighs whether it suits a particular case.
There are also practical differences inside this family that have nothing to do with receptors, including how a medicine is taken. The trade-offs between swallowed and injected formats in this class are set out in our comparison of oral versus injectable options.
One point worth holding onto: being newer or acting on more receptors does not automatically make a medicine the right choice for a given person. Side effect tolerance, other health conditions, other medicines, pregnancy plans and cost all enter the decision, and a prescriber weighs them together.
It is used in two settings, the management of type 2 diabetes and the management of overweight and obesity, both under prescriber supervision.
In the diabetes setting, the goal is glycaemic control, meaning steadier blood glucose across the day and a better three-month average. In the weight setting, the goal is body weight and the metabolic strain that comes with excess fat mass, including insulin resistance 3.
Those two uses overlap more than they look. Elevated blood sugar and excess fat mass share the same underlying machinery, so a medicine that acts on appetite, gastric emptying and insulin signalling touches both at once.
What it is not used for matters too. It is not a short cosmetic intervention, not a substitute for protein intake, resistance training or sleep, and not something to layer on top of an aggressive calorie deficit without supervision. Muscle mass and micronutrient status are real concerns when intake drops, which is one reason body composition and blood work are part of structured medical weight management rather than optional extras.
A licensed provider evaluates whether this medicine is appropriate at all, and that evaluation covers the goal, the starting point and everything else a person is managing.
Research suggests that, in people with type 2 diabetes, this medicine improved glycaemic control more than the comparator medicines examined in a systematic review and meta-analysis 5.
Glycaemic control is measured in two ways that answer different questions. Fasting glucose is a single morning snapshot. The three-month average, read from glycated haemoglobin, smooths out the day-to-day noise and shows the trend. Reviews of this medicine in type 2 diabetes describe improvement in that average alongside weight reduction 6.
What that means practically is modest and worth stating plainly. A medicine that flattens post-meal glucose and improves insulin signalling shifts the average downward over months, not days, because the marker itself reflects months. A reading taken two weeks after any change in management has barely begun to move.
It also means lab work is the follow-up tool, not the scale alone. Two people can see the same change on the scale and very different changes in their glucose markers, because fat distribution, muscle mass, sleep and training differ. Your prescriber decides what to check, when to check it, and what the pattern means for the next step.
Reviews of this medicine in overweight and obesity report reduction in body weight when it is prescribed as part of supervised management 7 8.
The mechanism behind that is the same one described earlier. Appetite signalling shifts, meals end sooner, gastric emptying slows, and total intake falls without the constant negotiation that white-knuckle dieting requires. Research suggests that the metabolic benefit extends to insulin resistance, which is the hinge between excess fat mass and rising glucose 3.
No figure on this page predicts an individual result, and no honest page can give you one. Published averages come from supervised populations with specific entry criteria, and the person in front of a clinician is not an average. Response varies, side effect tolerance varies, and some people are not suitable candidates at all.
What the published picture does support is a framing: this is a medicine that changes the physiology of appetite and glucose handling, used inside a structured approach that still includes protein intake, resistance training, sleep and follow-up blood work. Treatment decisions belong to a licensed provider who has reviewed the whole picture.
A licensed prescriber considers tirzepatide for adults being managed for type 2 diabetes or for overweight and obesity, and that consideration always starts with an evaluation rather than a request.
What the evaluation covers is fairly consistent. A prescriber reviews current and past medical conditions, every other medicine and supplement being taken, personal and family history of certain thyroid cancers, any history of pancreatitis or gallbladder problems, significant digestive conditions, kidney function, eating disorder history, and whether a person is pregnant, planning a pregnancy or breastfeeding. Recent lab work gives the metabolic starting point. Goals and timeline give the context.
Some of those findings rule the medicine out. Some change how closely a person is followed. Some simply mean a different approach fits better. That filtering is the point of the evaluation, and it is why no page can tell you whether you are a candidate.
If you want to know what that assessment looks like before booking one, our walkthrough of a telehealth evaluation for this class of medicine covers the history, labs and follow-up involved.
One more framing point. A prescription is a clinical decision made by a licensed provider about a specific person, with ongoing review built in. It is not a product you qualify for by answering a questionnaire quickly.
Hemoglobin A1C is the marker that shows average blood glucose over the preceding two to three months, expressed as the percentage of haemoglobin that has glucose attached to it.
Glucose binds to haemoglobin inside red blood cells in proportion to how much glucose is in the blood. Because red cells live for roughly three months, the percentage of glycated haemoglobin acts as a slow-moving average, weighted toward the recent weeks.
| Marker | FitScript optimal range | Your lab's own reference range |
|---|---|---|
| Hemoglobin A1C | 4.6 to 5.3 % | As printed on your lab report |
FitScript's optimal range is an optimization target, not a diagnostic cut-off. The reference range printed beside your own result is the one your lab applies, and reference ranges vary by lab, age and sex. A result outside a range is information to interpret, never a diagnosis on its own.
Read it as a trend. One value tells you where the average sat. Three values across a year tell you which direction the metabolism is moving, which is the question that actually matters when anything about nutrition, training or prescribed management changes.
A higher result reflects a higher average blood glucose over the preceding months, and a lower-than-expected result does not always mean better glucose control.
On the higher side, the observation is an elevated three-month average. What it may reflect includes insulin resistance, a carbohydrate intake pattern the body is not clearing well, poor sleep, chronic stress, low activity, or weight gain around the midsection. It can also reflect changes in medicines being taken for other conditions. The next step is not self-diagnosis; it is bringing the result, the trend and your symptoms to a clinician who can interpret them alongside fasting glucose and insulin.
On the lower side, a result that sits unexpectedly low can reflect something about red blood cells rather than glucose. Anything that shortens red cell survival shifts the number down, including recent blood loss, certain anaemias, some inherited haemoglobin variants, and pregnancy. In people with significant kidney or liver disease, the marker can also read differently from the true glucose average.
The honest summary is that this marker is a strong trend tool and an imperfect single snapshot. A suboptimal value is worth discussing with a clinician, and a value that moves sharply between tests is worth discussing promptly rather than waiting for the next scheduled panel.
It is tested from a standard blood sample, and fasting is not required because the marker reflects months of average glucose rather than that morning's meal.
Drawing it alongside fasting glucose and fasting insulin is useful, and those two do need a fasting window. Laboratories use different measurement methods, so results from two different labs are not perfectly interchangeable, and comparing a trend within one lab is more informative than comparing across them.
Things that move the number without glucose control changing include red blood cell turnover, iron deficiency and its correction, recent transfusion, pregnancy, inherited haemoglobin variants, and advanced kidney disease. Things that move the number because glucose control genuinely changed include shifts in carbohydrate intake and meal timing, resistance training and daily movement, sleep debt, illness and inflammation, weight change, and any prescribed management decided by your clinician.
Timing matters when you interpret a repeat test. Because the marker averages months, retesting a few weeks after any change tells you very little. Spacing repeat testing across months gives the marker time to reflect the change, and your clinician decides what that interval should be for you.
The three-month glucose average is more useful when it is read beside the markers that explain it, rather than on its own.
The cluster clinicians look at together includes fasting glucose and fasting insulin, which separate a high average driven by insulin resistance from one driven by inadequate insulin output. A lipid panel including triglycerides, HDL and ApoB fills in cardiometabolic risk, since triglyceride and HDL patterns shift with insulin resistance. Liver enzymes such as ALT and AST matter because the liver stores excess energy when insulin signalling is impaired. Kidney markers including creatinine and eGFR matter both for interpretation and for prescribing decisions. A complete blood count is quietly important here, because red cell indices and iron status change how the glycated haemoglobin result should be read. Thyroid markers and body composition round out the picture.
FitScript's model is built around that kind of repeat panel, with 150+ biomarkers tested per year and interpretation from Atlas, FitScript's AI health advisor, before a licensed clinician reviews what the pattern means for you.
The side effects described in published reviews are led by digestive symptoms, and they are the reason follow-up exists.
Reviews report that use of this medicine is associated with gastrointestinal effects including nausea, vomiting, diarrhoea and constipation in some people 5. Reduced appetite is part of how it works and can shade into inadequate intake if protein and fluids are not tracked. Reviews also describe hypoglycaemia among the outcomes examined when it is prescribed alongside other glucose-lowering management, which is one of the reasons a prescriber reviews every other medicine before deciding anything 5. Reference summaries of this medicine also note pancreatitis and gallbladder problems among the serious concerns a prescriber monitors for 9.
Some people experience skin reactions where the medicine is given. Some people experience none of these effects, and some stop because the digestive symptoms do not settle. That variation is normal and is exactly what follow-up visits exist to catch.
The practical rule is simple. Digestive symptoms that are manageable get reported to your prescriber at the next check. Symptoms that stop you keeping fluids down get reported promptly. The emergency signs listed further down do not wait for an appointment at all.
A licensed prescriber decides how tirzepatide is prescribed, how it is adjusted and how long it continues, and that is not information a general article can supply.
What a general article can describe is the shape of the follow-up. There is a baseline that includes history, current medicines, measurements and lab work. There are check-ins that cover symptoms, intake, digestive tolerance and how daily life is going. There is repeat lab work spaced far enough apart that the three-month glucose average has time to move. There are decisions along the way about continuing, adjusting or stopping, and all of them belong to the prescriber in conversation with the person taking the medicine.
Two things get missed when people manage this casually. The first is protein and resistance training, because losing weight without defending muscle mass changes body composition in a direction nobody wants. The second is the rest of the panel, because liver, kidney, lipid and blood count markers all carry information that the scale does not.
Stopping, restarting or changing anything about a prescription is a clinical decision, not a self-service one. Bring the question to the person who prescribed it.
The FitScript Essential panel is one set of lab work a reader can look at when the topic is metabolic health, including the three-month glucose marker. A licensed clinician reviews those results, decides what they mean in the context of your history and symptoms, and decides what comes next. Lab values describe patterns over time; they do not describe a person on their own.
Chest pain, fainting, or trouble breathing: call 911 or go to the emergency department.
Call 911 or go to the emergency department for:
Contact your prescriber for:
If you are pregnant, planning a pregnancy or breastfeeding, ask your OB or midwife as well as your prescriber before anything is decided. Never ignore an abnormal result, and never stop or change prescribed management on your own.
This page is educational and not medical advice. Discuss your results and any prescribed medicine with a clinician or licensed provider who knows your history.
If you are weighing this kind of medicine, the next step is a conversation with a FitScript clinician, and the hubs for medical weight loss for men and medical weight loss for women explain how that evaluation is structured.
Not quite. It acts on the GLP-1 receptor and also on a second gut hormone receptor called GIP, while the older medicines in the family act on GLP-1 alone. A licensed provider decides whether tirzepatide is appropriate for a particular person after a full evaluation.
No. It is used in the management of type 2 diabetes and also in the management of overweight and obesity, and a licensed prescriber decides which setting applies, if either does. Being interested in it is not the same as being a candidate for it, and only an evaluation can answer that.
Through follow-up with your prescriber, which includes symptoms, measurements and repeat blood work. The three-month glucose average moves slowly, so retesting a couple of weeks after a change tells you almost nothing. Your clinician decides which markers to check and how far apart to space them.
That is a decision to make with the person who prescribed it, not on your own. Appetite signalling and glucose handling can shift again once a medicine is no longer in the picture, so a prescriber plans what comes next rather than leaving a gap. Call your prescriber before stopping for any reason, including side effects.
Report it to your prescriber, who decides what to change. If you cannot keep fluids down or you have signs of dehydration, contact them promptly rather than waiting for your next appointment. Severe abdominal pain that does not ease, especially with vomiting or pain spreading to the back, means calling 911 or going to the emergency department.
Ask your OB or midwife, and tell your prescriber if you are pregnant, planning a pregnancy or breastfeeding. Pregnancy changes the whole calculation around any prescription medicine, and that conversation belongs to the clinicians who are looking after you. Do not make the call on your own.
No. Protein intake, resistance training, sleep and daily movement still do the work of protecting muscle mass and metabolic health while body weight changes. A licensed provider who prescribes tirzepatide builds those elements into the follow-up rather than leaving them out, because the scale alone does not describe body composition.